Market access for specialist medicines in the UK: the Price is Right?

5th May 2015

Market access for specialist medicines in the UK: the Price is Right?Andrew McConaghie

A recent pharmaphorum webinar brought four experts together to discuss the future of market access for specialist medicines in the UK. IMS Health's Angela McFarlane, Shire's Alan Kane, the Cystic... Read more

The outlook for HIV drug development

1st May 2015

The outlook for HIV drug development Moritz Herrmann

The HIV market is shifting towards integrase inhibitor-based single-tablet regimens – but emerging markets such as Brazil and China are hesitant to pay the cost.Since the first anti-HIV drug Retrovir... Read more

7 Questions: Vincent Varlet on digital technology for health

30th April 2015

7 Questions: Vincent Varlet on digital technology for healthVincent Varlet

pharmaphorum spoke to the executive director for marketing and communication at Novartis Pharma in France about his views on digital healthcare and technology.What is your involvement in digital healthcare/healthcare technology?I... Read more

Tapping Latin America’s healthcare market

29th April 2015

Tapping Latin America’s healthcare marketGuillaume Corpart

Guillaume Corpart outlines the current and future health environment in the region, pinpointing the markets ripe for development in this first of a two-part series.A decade of prosperity in Latin... Read more


Novo Nordisk invests in haemophilia franchise

5th May 2015

Novo Nordisk invests in haemophilia franchiseStaff reporter

Novo Nordisk has started work on a 1.5 billion kroner ($225 million) manufacturing facility in Denmark to support the expected growth in its haemophilia franchise.Once fully operational in 2020, the... Read more

Viralytics lifted by FDA panel verdict on T-Vec

1st May 2015

Viralytics lifted by FDA panel verdict on T-VecStaff reporter

The positive verdict of the US FDA's Oncologic Drugs Advisory Committee (ODAC) on Amgen's T-Vec (talimogene laherparepvec) is proving a boost to other companies developing oncolytic immunotherapies, including Australia's Viralytics.Earlier... Read more

Mylan and Teva trade blows as Perrigo backs away

30th April 2015

Mylan and Teva trade blows as Perrigo backs awayStaff reporter

Teva and Mylan are continuing to press their takeover bids in an increasingly hostile M&A chain, while Perrigo remains staunch in its defence.Ireland-based Perrigo has just rejected Mylan's third offer... Read more

Sanofi’s diabetes drug Toujeo approved in Europe

30th April 2015

Sanofi’s diabetes drug Toujeo approved in EuropeAndrew McConaghie

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe.Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes... Read more

Audio & Video

Live debate/webinar: The Future of Medic…



The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…


Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

On demand webinar: Staring into the aby…

IMS webinar


Regardless of the colour of the next UK government that emerges as a result of the May election, the £30–50bn NHS budget... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate



COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

White Papers

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

Further News & Articles

AstraZeneca gains fast-track review for Brilinta

The US FDA has granted AstraZeneca's (AZ) Brilinta a priority review for patients with a history of heart att... Read more


Takeda settles Actos damages case for $2.7bn

Takeda has agreed to pay an eye-watering $2.7 billion to settle claims that its diabetes drug Actos caused bladd... Read more


Merrimack hoping for first product approval this year

The US FDA has accepted Merrimack's rolling application to market its first product, the second-line pancreatic ... Read more


Opdivo set to be first PD-1 approved in Europe

Bristol-Myers Squibb's (BMS) new cancer immunotherapy Opdivo has been recommended by Europe's CHMP committee – j... Read more


Early access initiatives – one year on

Both the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) lau... Read more


AZ's Celgene tie-up 'will boost immuno-oncology business'

AstraZeneca (AZ) has forged an alliance with Celgene to accelerate the development of its checkpoint inhibitor M... Read more